Andres Caero Romero, MD
Nephrology · Ardmore, OKNPI 1902193865
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 99.9% of the total across 250 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 24 manufacturers, the largest accounting for just 17.4% — the pattern of someone who eats at a lot of different presentations.
Across 250 payments — averaging $16.72 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Fresenius USA Marketing, Inc.$728
- AstraZeneca$626
- Travere Therapeutics, Inc.$570
- Amgen$462
- Bayer$401
- GSK$203
- plus $1K from 18 others
What the payments were for
- Food & beverage$4,176100%
- Education$50%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Fresenius USA Marketing, Inc. | 53 | $728 |
| AstraZeneca | 36 | $626 |
| Travere Therapeutics, Inc. | 30 | $570 |
| Amgen(2 entities) | 24 | $462 |
| Bayer | 28 | $401 |
| GSK | 15 | $203 |
| Vifor Pharma, Inc. | 10 | $176 |
| OPKO Pharmaceuticals, LLC | 9 | $146 |
| Calliditas Therapeutics US Inc. | 7 | $137 |
| Ardelyx, Inc. | 6 | $105 |
| Boehringer Ingelheim | 6 | $97 |
| Novartis | 5 | $95 |
| Lilly USA, LLC | 4 | $87 |
| ANI Pharmaceuticals, Inc. | 3 | $61 |
| Otsuka Pharmaceutical Development & Commercialization, Inc. | 4 | $55 |
| Veloxis Pharmaceuticals, Inc. | 1 | $40 |
| Scpharmaceuticals Inc. | 1 | $38 |
| Sanofi-aventis U.S. LLC | 2 | $33 |
| Novo Nordisk | 1 | $30 |
| Vantive US Healthcare LLC | 1 | $24 |
| Akebia Therapeutics Inc | 1 | $20 |
| Mallinckrodt Enterprises LLC | 1 | $18 |
| Otsuka America Pharmaceutical, Inc. | 1 | $13 |
| Mallinckrodt Hospital Products Inc. | 1 | $13 |
How this compares
$4,181 in reported general payments places this provider in the 65th percentile of 106 nephrology providers in Oklahoma.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| JardianceEmpagliflozin | 339 | $219,276 |
| FarxigaDapagliflozin Propanediol | 70 | $45,820 |
| VelphoroSucroferric Oxyhydroxide | 11 | $35,640 |
| KerendiaFinerenone | 23 | $16,123 |
| Sevelamer Carbonate | 85 | $13,530 |
| JanuviaSitagliptin Phosphate | 24 | $13,323 |
| Furosemide | 348 | $3,041 |
| Losartan Potassium | 99 | $2,260 |
| Torsemide | 66 | $2,124 |
| Calcium Acetate | 33 | $2,110 |
| Calcitriol | 154 | $2,023 |
| Amlodipine Besylate | 175 | $1,980 |
| Cinacalcet Hcl | 25 | $1,866 |
| Bumetanide | 71 | $1,288 |
| Carvedilol | 25 | $1,253 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Boehringer IngelheimJardiance | $97 | $219,276339 claims |
| AstraZenecaFarxiga | $626 | $45,82070 claims |
| Fresenius USA Marketing, Inc.Velphoro | $728 | $35,64011 claims |
| BayerKerendia | $401 | $16,12323 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 65th percentile of 106 nephrology providers in Oklahoma.
Other nephrology in Ardmore
- Celeste BoeckmanOklahoma City$90K
- Joseph GhataOklahoma City$45K
- Sunil AgrawalTulsa$40K
- Benjamin CowleyOklahoma City$36K
- Pranay KathuriaTulsa$21K
- Kevin FuTulsa$14K
- Diptesh GuptaTulsa$13K
- Brad CarterOklahoma City$13K
- Janet RussellTulsa$12K
- Bobby MuthalalyTulsa$12K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.